

FW

1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Horn  
Appl. No.: 09/854,414  
Conf. No.: 7675  
Filed: May 10, 2001  
Title: OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE  
Art Unit: 1614  
Examiner: Z. Fay  
Docket No.: 114309-1007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

**OTHER DOCUMENTS**

Refractive Surgery, June 22, 2000, [http://www.eyecare.com/refractive\\_surgery.html](http://www.eyecare.com/refractive_surgery.html)

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Robert M. Barrett  
Reg. No. 30,142  
P.O. Box 1135  
Chicago, Illinois 60690-1135  
Phone: (312) 807-4204

Dated: August 20, 2004

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> (Use several sheets if necessary)  PTO Form 1449	Atty Docket No. 114309-1007	Application No. 09/854,414
	Applicant Gerald Horn	
	Filing Date May 10, 2001	Group 1614

U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

Examiner's Initials		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
		Refractive Surgery, June 22, 2000, <a href="http://www/eyecarest.com/frefractive_surgery.html">http://www/eyecarest.com/frefractive_surgery.html</a>


Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) of 1.97(c))					Docket No. 114309-1007	
In Re Application Of: <b>Gerald Horn</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
09/854,414	May 10, 2001	Z. Fay	24573	1614	7675	
Title: <b>OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE</b>						
<div style="text-align: center;"> <p>Address to:</p> <p><b>Commissioner for Patents</b>  <b>P.O. Box 1450</b>  <b>Alexandria, VA 22313-1450</b></p> <p><b>37 CFR 1.97(b)</b></p> <p>1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="margin-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center; margin-left: 100px;"><b>OR</b></p> <p style="margin-left: 40px;"><input checked="" type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p> </div>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
114309-1007

In Re Application: Gerald Horn



Application No. 09/854,414	Filing Date May 10, 2001	Examiner Z. Fay	Customer No. 24573	Group Art Unit 1614	Confirmation No. 7675
-------------------------------	-----------------------------	--------------------	-----------------------	------------------------	--------------------------

**OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of \$180.00 is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on 08-20-04 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Karin Barrett

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

Signature

Dated: August 20, 2004

Robert M. Barrett  
Reg. No. 30,142  
BELL, BOYD & LLOYD LLC  
P.O. Box 1135  
Chicago, IL 60690-1135  
Phone: 312-807-4204

CC:

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(d) and 1.97(c))					Docket No. 114309-1007	
In Re Application Of: <b>Gerald Horn</b>						
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.	
09/854,414	May 10, 2001	Z. Fay	24573	1614	7675	
Title: <b>OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE</b>						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
<b>37 CFR 1.97(b)</b>						
1. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
<b>37 CFR 1.97(c)</b>						
2. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<div style="margin-left: 40px;"> <input type="checkbox"/>   the statement specified in 37 CFR 1.97(e);         </div>						
<b>OR</b>						
<div style="margin-left: 40px;"> <input checked="" type="checkbox"/>   the fee set forth in 37 CFR 1.17(p).         </div>						

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

(Under 37 CFR 1.97(b) for 1.97(c))

Docket No.  
114309-1007

In Re Application: Gerald Horn

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

09/854,414

May 10, 2001

Z. Fay

24573

1614

7675

**OPHTHALMIC FORMULATIONS COMPRISING IMIDAZOLINE****Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☒ A check in the amount of **\$180.00** is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **02-1818** as described below.
- ☐ Charge the amount of
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No.

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I certify that this document and fee is being deposited on **08-20-04** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Signature of Person Mailing Correspondence

Karin Barrett

Typed or Printed Name of Person Mailing Certificate

**\*This certificate may only be used if paying by deposit account.**

Signature

Dated: August 20, 2004

Robert M. Barrett

Reg. No. 30,142

BELL, BOYD &amp; LLOYD LLC

P.O. Box 1135

Chicago, IL 60690-1135

Phone: 312-807-4204

cc: